Back Pain News and Research

Latest Back Pain News and Research

Canadians with chronic neck and back pain now have access to top spinal care

Canadians suffering from chronic and severe neck and back pain now have access to the top spinal care available. Spinal heath expert, Dr. Ron Nusbaum, has launched Back Clinics of Canada, a state-of-the-art facility that focuses on educating patients on the importance of spinal health and offering cutting-edge care that can bring an end to back pain.

25 Nov 2009

Minimally invasive procedure relieves chronic back pain for retired school teacher

Carole Riggs, a retired teacher and school principal, points to her work during one Christmas vacation - bending, twisting and sitting on the floor to create games and teaching aids - as the primary culprit behind many years of back pain.

24 Nov 2009

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009

GOT YOUR BACK launches The Spinalis Chair

GOT YOUR BACK will be hosting an Open House at their retail location at 521 East Hector Street, Conshohocken, PA on December 12th from 1:00 p.m. - 4:00 p.m. Guests will include health and wellness professionals, chiropractors, massage therapists and those interested in alternative fitness and wellness throughout the tri-state area. Visitors will enjoy food, beverages, a free chair massage, and free on site diagnosis of the spine. This event is also open to the public and special discounts will be offered throughout the store exclusively for attendees of this event.

20 Nov 2009

Smartfish Technologies' patented ErgoMotion technology unveiled

Today, Smartfish Technologies launched its long-awaited ErgoMotion(TM) technology, the first ever design that combines the science of ergonomics with the technology of motion, resulting in a dramatic change and improvement in the way comfort is integrated into devices like mice and keyboards. Unveiled yesterday at Pepcom’s annual Wine, Dine and Demo event, ErgoMotion is the industry’s most advanced computer peripheral solution designed to relieve discomfort and repetitive stress injuries (RSI) related to extended computer usage.

20 Nov 2009

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).

19 Nov 2009

Tips for staying safe and healthy during Thanksgiving holiday

Visiting is a big part of the Thanksgiving holiday. But one place you don't want to stop by is the Emergency Department.

19 Nov 2009

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

St. Jude Medical, Inc. announced today that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.

18 Nov 2009

Majority of mothers personally manage their children's health this coming winter

Three out of four mothers with a child between the ages of two through 12 are extremely, very, or somewhat concerned about their child's health this coming winter, according to a survey conducted by Opinion Research Corporation and commissioned by Bionorica, an international company pioneering clinical research of natural remedies including Sinupret® for Kids, a product which supports healthy respiratory function in children (www.bionoricausa.com).

18 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the neuropathic pain drug market -- driven by the launches of several novel therapies -- will increase from $6 billion in 2008 to $9.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

16 Nov 2009

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

Spine Care Institute established by Hospital for Special Surgery

Hospital for Special Surgery today announced the establishment of one of the most comprehensive centers of excellence in the country for the treatment of all nonoperative and operative spine disorders.

16 Nov 2009

Doctors face image problems; patients deal with shortages, are urged to question care

Doctors must not only face the fading image of primary care providers, but also physician shortage issues. Meanwhile, some experts suggest patients consider saying "no" to their doctor to control health care costs.

13 Nov 2009

SpinalMotion submits Kineflex lumbar artificial disc PMA to FDA

SpinalMotion, developer of the investigational Kineflex® lumbar and Kineflex/C® cervical disc implants for treating patients with degenerative disc disease (DDD), today reported that it has submitted the Pre-Market Approval (PMA) to FDA for the Kineflex lumbar artificial disc

13 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010.

13 Nov 2009